Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
May 11, 2023
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2024
Jan. 31, 2023
Intangible assets   $ 3,549,427   $ 3,549,427  
Impairment on intangible assets       0 $ 0
Impairment charges       $ 0 0
Number of shares repurchased 8,085,879 178,833   256,942  
Payments for repurchase of common stock   $ 404,717   $ 27,022,987 9,254,005
Accrued excise tax   270,230   270,230  
Research and development expenses   126,732 $ 45,393 313,248 382,662
Federal deposit insurance amount   250,000   250,000  
Cash uninsured amount   16,480,000 $ 1,100,000 $ 16,480,000 $ 1,100,000
Common Stock [Member]          
Number of shares repurchased       8,342,821  
Payments for repurchase of common stock       $ 27,293,217  
Cell In A Box [Member]          
Intangible assets   1,549,427   1,549,427  
Diabetes License [Member]          
Intangible assets   $ 2,000,000   $ 2,000,000  
S G Austria [Member]          
Equity percentage   14.30%   14.30%